Ephedra alkaloids inhibit platelet aggregation

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 3, 2010, Pages 266-271

  Watson, Rex ^a,b   Woodman, Ryan ^a,c   Lockette, Warren ^a,c,d  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alpha 2 adrenergic receptor; Amphetamine; Ephedrine; Hemorrhage; Phenylpropanolamine; Stroke; Sympathomimetics

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALKALOID; AMPHETAMINE; ANOREXIGENIC AGENT; CAFFEINE; CYCLIC AMP; EPHEDRA ALKALOID; EPHEDRINE; PADGEM PROTEIN; PHENYLPROPANOLAMINE; RANTES; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; BLEEDING TENDENCY; BLOOD PRESSURE; DRUG EFFECT; EPHEDRA; EX VIVO STUDY; HUMAN; NORMAL HUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; TREATMENT INDICATION;

ALKALOIDS; ASPIRIN; BLOOD PLATELETS; CAFFEINE; EPHEDRA; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SIGNAL TRANSDUCTION; SYMPATHOMIMETICS;

EID: 77950240692     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328337b39f     Document Type: Article

References (30)

1. Chen KK, Schmidt CF. Ephedrine and related substances. Medicine 1930; 19:1-97.
2. Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids. Prog Cardiovasc Dis 2005; 47:217-225.
3. Department of Health and Human Services, Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk: final rule. Fed Regist 2004; 69:6787-6854.
4. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldman E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826-1832.
5. Cantu C, Arauz A, Murillo-Bonilla LM, Lopez M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003; 34:1667-1673.
6. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing Ephedra alkaloids. N Engl J Med 2000; 343:1833-1838.
7. MacFarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinaseactivated receptors. Pharmacologic Rev 2001; 53:245-282.
8. Marquis NR, Becker JA, Vigdahl RL. Platelet aggregation: an epinephrineinduced decrease in cAMP synthesis. Biochem Biophys Res Comm 1970; 39:783-789.
9. Vaugeois JM, Ledent C. Aggressiveness, hypoalgesia, and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997; 388:674-678.
10. Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA 1987; 258:236-239.
11. Jordan J, Shannon JR, Diedrich A, Black B, Robertson D, Biaggioni I. Water potentiates the pressor effect of Ephedra alkaloids. Circulation 2004; 109:1823-1825.
12. Burn JH, Rabd MJ. The action of sympathomimetics amines in animals treated with reserpine. J Physiol 1958; 144:314-336.
13. Cannon C, Cowan FF, Kopanyl T, Maengwyn-Davies GD. Explanation of cocaine desensitization of blood pressure responses to ephedrine. Science 1961; 134:1075-1077.
14. Eble JE. A study of the mechanisms of the modifying actions of cocaine, ephedrine, and imipramine on the cardiovascular response to norepinephrine and epinephrine. J Pharm Exp Ther 1964; 144:76-82.
15. Trendelenburg U, de la Sierra BGA, Musko A. Modification by reserpine on the response of the atrial pacemaker to sympathomimetic amines. J Pharmacol Exp Ther 1963; 141:301-309.
16. Lilies JT, Dabisch PA, Hude KE, Pradhan L, Varner KJ, Porter JR, et al. Pressor responses to ephedrine are mediated by a direct mechanism in the rat. J Pharmacol Exp Ther 2006; 316:95-105.
17. Flavahan NA. Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating a-2 adrenoreceptors. J Pharmacol Exp Ther 2005; 313:432-439.
18. Rothman RB, Vu N, Partilla JS. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 2003; 307:138-145.
19. Ma G, Bavadekar SA, Davis YM. Pharmacological effects of ephedrine alkaloids on human a1-and a-2-adrenergic receptor subtypes. J Pharm Exp Ther 2007; 322:214-221.
20. Persky AM, Berry NS, Pollack GM, Brouwer KLR. Modeling the cardiovascular effects of ephedrine. Br J Clin Pharmacol 2004; 57:552-562.
21. Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O'Brien PJ, et al. Loss of signaling through the G protein, Gz results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A 2000; 97:9984-9989.
22. Farrow S, Mers A, Steigerwalt S, Sowers J, Banta G, Lockette W. The effect of the alpha-2 adrenergic antagonist yohimbine on orthostatic tolerance. Hypertension 1990; 15:877-880.
23. Spalding A, Vaitkevicius H, Dill S, Schmaier A, Lockette W. Mechanism of epinephrine-induced platelet aggregation. Hypertension 1998; 31:603-607.
24. Glick R, Hoying J, Cerullo L, Perlman S. Phenylpropanolamine: an over-thecounter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. Neurosurgery 1987; 20:969-974.
25. Cattaneo M. The P2 receptors and congenital platelet function defects. Sem Thromb Hemostasis 2005; 31:168-173.
26. Sun B, Li H, Shakur Y. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007; 19:1765-1771.
27. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? Metabolism 1992; 41:1233-1241.
28. Harding SA, Sarma J, Din JN, Maciocia PM, Newby DE, Fox KAA. Clopidogrel reduces platelet-leukocyte aggregation, monocyte activation, and RANTES secretion in type II diabetes mellitus. Heart 2006; 92:1335-1337.
29. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354:1445-1448.
30. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psych 2005; 66:253-259.